Tests mepivacaine injections for neurological effects after ischemic stroke
Tests a mepivacaine injection under the skin in adults with stroke-related neurological symptoms.
Plain-language title generated from the registry record
Registry title: MEPI-AVC - Evaluation of the efficacy and safety of mepivacaine on the neurological sequelae of cerabral infarction
Key facts
- Where
- Paris Cedex 13, FranceSee the site
- Phase
- Phase 2
Where in France
- Assistance Publique Hopitaux De ParisParis Cedex 13, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique Hopitaux De Paris
- Trial code
- NCT05222828EU 2024-514481-39-00
- Record updated
- 22 April 2026
- Original description
To assess, in patients with neurological symptoms following ischemic stroke, the rate of responders to an injection of mepivatin subcutaneouslyRead full original descriptionShow less
MEPI-AVC - Evaluation of the efficacy and safety of mepivacaine on the neurological sequelae of cerabral infarction
To assess, in patients with neurological symptoms following ischemic stroke, the rate of responders to an injection of mepivatin subcutaneously
Inclusion: Ischemic stroke more than 30 days old Age between 18 and 85 years old At least one deficit among: motor deficit: score < 56 on the Fugl-Meyer scale aphasia: score ≥4 on the Aphasia Rapid Test, presence of a clinically observable visual scotoma Having given their written consent Be affiliated with a social security scheme, Universal Medical Coverage (CMU) or any equivalent scheme.
Exclusion: Hypersensitivity to amide-bonded local anesthetics. Atrioventricular conduction disorders requiring permanent electro-systolic training not yet performed. Epilepsy not controlled by treatment. Porphyritic subjects. Patients with a motor deficit (but no aphasia or scotomas) in whom there is spasticity leading to a major reduction in joint amplitude in passive motion Minor patients, under curatorship or guardianship, under legal protection, deprived of liberty, pregnant or breastfeeding women Pathologies involving the vital prognosis or compromising follow-up during the study period Patient undergoing local amine anesthesia in the 7 days preceding V1. Patients currently treated with no anti-arrhythmics such as tocainide, aprindine and mexiletine Patients with a contraindication to MRI (ferro-magnetic surgical clips, eye implants, metallic foreign body intraocular or in the nervous system, implants or metallic objects likely to contain the radiofrequency field, cochlear implants, cerebral or cardiac pacemaker , implantable cardiac defibrillators) Patients participating in research involving the therapeutic human person who may modify functional recovery (whether by medication or by medical device) or subject to an exclusion period for another research.